Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry.
Summary
In 35,826 MI patients discharged on high-intensity statins, adding ezetimibe within 12 weeks was associated with lower MACE than delayed addition or no addition. Early combination therapy also showed lower cardiovascular mortality versus delayed or no escalation, supporting early ezetimibe as standard post-MI care.
Key Findings
- Among 35,826 MI patients, 1-year MACE rates per 100 patient-years were 1.79 (early), 2.58 (late), and 4.03 (none).
- Compared with early combination therapy, 3-year HR for MACE was 1.14 (95% CI 0.95–1.41) for late and 1.29 (95% CI 1.12–1.55) for no ezetimibe.
- Cardiovascular death at 3 years was higher with late (HR 1.64) and no ezetimibe (HR 1.83) vs early addition.
- High-intensity statin use was ≥98% across groups, isolating the added value of early ezetimibe.
Clinical Implications
Post-MI pathways should routinely initiate statin-ezetimibe combination before discharge or within 12 weeks to avoid preventable MACE and cardiovascular deaths; stepwise delay may be harmful.
Why It Matters
Addresses a pervasive care gap—delayed escalation after MI—using modern causal inference, showing clinically meaningful risk reductions with early combination LLT.
Limitations
- Observational design with residual confounding despite advanced causal methods
- Generalizability outside Sweden and to PCSK9-based strategies requires further study
Future Directions
Pragmatic randomized or stepped-wedge trials of early combination LLT, cost-effectiveness across systems, and integration into discharge order sets.
Study Information
- Study Type
- Cohort
- Research Domain
- Treatment
- Evidence Level
- III - Large observational registry analysis with causal inference methods
- Study Design
- OTHER